Intersect ENT (XEXT) Stock Gains After Upsizing Secondary Offering

NEW YORK (TheStreet) -- Intersect ENT  (XENT) shares are climbing 2.5% to $25.79 in trading on Wednesday after the commercial stage drug device company upsized its secondary offering by 582,000 shares to 3.582 million shares.

The company priced its offering at $25 per share, a slight decrease from yesterday's closing price of $25.16, resulting in aggregate proceeds of $89.6 million.

J.P. Morgan (JPM) and Bank of America/Merrill Lynch (BAC) are acting as joint book-running managers for the offering.

XENT Chart XENT data by YCharts

If you liked this article you might like

Strong On High Volume: Intersect ENT (XENT)

Insider Trading Alert - TRUP, XENT And EA Traded By Insiders

Trade-Ideas: Intersect ENT (XENT) Is Today's "Dead Cat Bounce" Stock

Intersect ENT (XENT) Strong On High Relative Volume Today

Strong On High Volume: Intersect ENT (XENT)